CD28 and neuroblastoma: GD2-directed CAR-T has previously demonstrated strong efficacy in neuroblastoma, with a recent phase I/II trial of patients with relapsed/refractory high-risk neuroblastoma treated with third-generation (CD28 + 4-IBB) GD2-specific CAR demonstrating an overall response of 63% and event-free survival of 36% [103].